Strides Shasun Concedes Acquisitions Harder To Swallow Than Expected As Earnings Disappoint
Arun Kumar, managing director of leading Indian pharmaceutical company Strides Shasun, was hailed as the man with the Midas touch when he sold the company’s injectable-medicine unit to Mylan Inc three years ago for a hefty $1.6bn. But his business-savvy reputation has taken a bit of a knock with Strides conceding the digestion of some recent acquisitions is taking longer than expected after the firm reported earnings which sent its shares tumbling.
You may also be interested in...
Strides Shasun founder Arun Kumar has moved back into the driver’s seat to focus on “course correction” after the Indian drug maker racked up an unexpected quarterly loss that triggered a massive share selloff.
Indian drug firm Strides Shasun has acquired the Australian unit of Amneal Pharmaceuticals, extending its customer footprint as it sets sights on becoming the leading player in the Australian generics market.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.